Overt Hepatic Encephalopathy Market Insight

DelveInsight’s ‘Overt Hepatic Encephalopathy (OHE) - Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the OHE, historical and forecasted epidemiology as well as the OHE market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The OHE market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM OHE market size from 2018 to 2030. The Report also covers current OHE treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Overt Hepatic Encephalopathy (OHE) Disease Understanding and Treatment Algorithm

Hepatic encephalopathy (HE) is a brain disorder that develops in some individuals with liver disease. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease. It is observed in acute liver failure, liver bypass procedures – for example, shunt surgery and trans-jugular intrahepatic portosystemic shunt – and cirrhosis, classified as Type A, B, and C HE, respectively. Pathogenesis is linked with ammonia and glutamine production.

 

Moreover, HE can be associated with more severe symptoms, including reduced alertness, shortened attention span, disruptions in sleep patterns, mild confusion, slowing ability to perform mental tasks, and mood or personality changes. More noticeable changes in memory, concentration, or intellectual function than in minimal hepatic encephalopathy (MHE) may also be observed. HE can also be classified according to whether its presence is overt or covert. When affected individuals have obvious, outward signs and symptoms, the disorder may be referred to as overt hepatic encephalopathy (OHE).

 

Overt Hepatic Encephalopathy (OHE) Diagnosis

The HE diagnosis is based on the presence of a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction after excluding unrelated neurologic and/or metabolic causes of encephalopathy. The diagnosis of OHE is made after excluding other causes of encephalopathy and mental status changes. In addition to making the diagnosis of OHE, it is imperative to identify and address precipitating factors of OHE, such as infection, upper gastrointestinal bleeding, medications, or electrolyte/volume disturbances.

 

Overt Hepatic Encephalopathy (OHE) Treatment

Management of OHE includes treating patients with acute HE episodes, preventing HE recurrence, and identifying and managing precipitating factors associated with HE development. The two primary forms of medical therapy for HE are nonabsorbable disaccharides (i.e., lactitol and lactulose) and nonabsorbable antibiotics (i.e., rifaximin). The hyperammonemia and inflammation that occurs due to urea breakdown in cirrhotics have led to the development of HE treatments that target gut bacteria. Treatments for OHE approved by the USFDA and some unapproved treatments are available for use. It is important to remember that in patients with cirrhosis and portosystemic shunting, skeletal muscle mass and renal clearance are vital to neurotoxin clearance.

Overt Hepatic Encephalopathy (OHE) Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Hepatic Encephalopathy, Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy, Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy, and Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

 

Key Findings

  • Total diagnosed prevalent cases of Hepatic Encephalopathy (HE) in the 7MM were found to be 337,013  in 2020.
  • The epidemiology model of OHE is based on the various published literature related to cirrhosis and its hospitalization. We also conducted interviews with the key opinion leaders (KOLs) to fill the gaps and confirm the findings of the secondary search.
  • Assessments as per DelveInsight analysis, the US accounted for the majority of Hepatic Encephalopathy cases in the 7MM with 205,018 diagnosed prevalent cases in 2020.
  • The age‐specific data revealed that the highest number of Hepatic Encephalopathy people affected with was found in the age group of 45–54 years, while people <25 years are the least affected.
  • Assessments as per DelveInsight’s analysts show that the majority of cases of Hepatic Encephalopathy are males. There was a total of 149,048 male and 55,970 female cases of Hepatic Encephalopathy in 2020 in the United States.
  • HE is divided into two broad categories based on severity, Covert Hepatic Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). There was a total of 82,007 OHE cases in 2020 in the United States which is expected to increase at a CAGR of 0.79% for the study period 2018-2030.
  • In EU-5, the United Kingdom has the highest number of cases of OHE with 10,971 cases in 2020, followed by Germany with 10,669 cases and France with 8,910 cases. While Spain reported the least number of cases i.e. 3,923 in 2020.
  • In 2020, Japan had 11,829 diagnosed prevalent cases of OHE. These cases are expected to increase by 2030 at a CAGR of 0.20%.

Country-Wise Overt Hepatic Encephalopathy (OHE) Epidemiology

The epidemiology segment also provides the Overt Hepatic Encephalopathy (OHE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Overt Hepatic Encephalopathy (OHE) Drug Chapters

The drug chapter segment of the Overt Hepatic Encephalopathy (OHE) report encloses the detailed analysis of Overt Hepatic Encephalopathy (OHE) marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Overt Hepatic Encephalopathy (OHE) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

 

Overt Hepatic Encephalopathy (OHE) Marketed Drugs

 

Xifaxan: Salix Pharmaceuticals/Bausch Health

Xifaxan (rifaximin) tablets (550 mg) developed and marketed by Salix Pharmaceuticals (a subsidiary of Valeant Pharmaceuticals), was indicated for the reduction in risk of Overt Hepatic Encephalopathy (HE) recurrence in patients ≥ 18 years of age. It is also being marketed to treat Travelers’ Diarrhea and IBS-D (Irritable Bowel Syndrome with Diarrhea). Salix is exploring the potential additional indications, formulations, and clinical trials, and co-promotion arrangements for Xifaxan to capitalize on the potential for Xifaxan, including development programs in Crohn’s disease and liver disease.

Products detail in the report…

 

Overt Hepatic Encephalopathy (OHE) Emerging Drugs

 

AXA1665: Axcella Health, Inc.

AXA1665—Axcella’s product candidate for a reduction in risk of recurrent overt hepatic encephalopathy (OHE)—is a composition of eight amino acids and derivatives designed to target multiple metabolic pathways intersecting key organ systems, including the liver, muscle, and gut. In prior clinical studies, this oral product candidate was safe, well-tolerated, and demonstrated the potential to improve ammonia handling, physical function, amino acid balance, and neurocognition with a safe and well-tolerated profile. Axcella conducted two studies for AXA1665: AXA1665-001 and AXA1665-002.

Products detail in the report…

 

GR3027 (Golexanolone): Umecrine Cognition

Umecrine Cognition, a Karolinska Development (KDEV), is developing novel GR3027 (golexanolone), an orally administrated small molecule to treat patients diagnosed with HE. Golexanolone is a GABAA-receptor modulating steroid antagonist (GAMSA) designed to antagonize positive GABAA-receptor modulation by endogenous neuroactive steroids.

Products detail in the report…

List to be continued in the report…

Overt Hepatic Encephalopathy (OHE) Market Outlook

Overt hepatic encephalopathy (OHE) may develop over hours or days and occur spontaneously or following an event, such as gastrointestinal bleeding, infection, dehydration, or constipation.

 

First-line therapy for patients experiencing an acute episode of OHE is the nonabsorbable disaccharide lactulose, which requires self-titration to two to three soft bowel movements per day.

 

The Second-line of therapy for the management of HE includes probiotics, polyethylene glycol 3350–electrolyte solution (PEG), ammonia scavengers, branched-chain amino acids (BCAA), protein restriction, zinc, and fecal microbiota transplant (FMT).

 

The role of nutrition in the management of HE has been the focus of renewed attention. An expert panel commissioned by the International Society for Hepatic Encephalopathy and Nitrogen Metabolism recommended that all patients with cirrhosis and HE should undergo baseline nutritional assessment and interval reassessments as part of management planning. Protein restriction should never be recommended in patients with cirrhosis (with or without HE).

 

The availability of well-established healthcare infrastructure in the United States also contributes to the growth of the market. In addition, an increasingly aging population and increased R&D investments by drug manufacturing companies are fueling the market expansion

 

According to DelveInsight, the market of OHE in 7MM is expected to change in the study period 2018–2030.

 

Key Findings

  • The therapeutic market of OHE in the 7MM was USD 1,047 million in 2020.
  • The therapeutic market of OHE in the United States was USD 831 million in the year 2020.
  • The first-line agent used to prevent acute or persistent OHE is the non-absorbable disaccharides (lactulose or lactitol). Extensive clinical experience has demonstrated the efficacy of oral non-absorbable disaccharides. Unfortunately, not all patients can tolerate these agents. The market size of Lactulose was USD 216 million in 2020.
  • The market size of Xifaxan (Rifaximin) approved for the reduction in risk of OHE recurrence in patients ≥ 18 years of age was USD 383 million in 2020.
  • The market size in the 7MM might increase at a CAGR of 3.59%. An increase in the diagnosed prevalence of OHE and the expected approval of emerging therapies are the primary factors driving the growth of the OHE market.
  • With the expected launch of upcoming therapies, such as MNK-6105(IV), and Rifaximin (SSD), the total market of OHE is expected to show a decent change in upcoming years.
  • The therapeutic market of OHE in Japan was USD 21 million in the year 2020.

 

The United States Market Outlook

This section provides the total Overt Hepatic Encephalopathy (OHE) market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total Overt Hepatic Encephalopathy (OHE) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Overt Hepatic Encephalopathy (OHE) market size and market size by therapies in Japan are provided.

Overt Hepatic Encephalopathy (OHE) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the OHE market or expected to get launched in the market during the study period 2018–2030. The analysis covers OHE market uptake by drugs, patient uptake by therapies, and sales of each drug.  

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Overt Hepatic Encephalopathy (OHE) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Overt Hepatic Encephalopathy (OHE) emerging therapies.

Reimbursement Scenario in Overt Hepatic Encephalopathy (OHE)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Overt Hepatic Encephalopathy (OHE) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

  • The report covers the descriptive overview of OHE, explaining its signs and symptoms, causes, diagnosis, and currently available therapies.
  • Comprehensive insight has been provided into the OHE epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for OHE is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the OHE market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM OHE market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the OHE market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence OHE R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition and underlying cause.
  • Major players are involved in developing therapies for OHE. The launch of emerging therapies will significantly impact the OHE market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Overt Hepatic Encephalopathy (OHE) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • OHE Pipeline Analysis
  • OHE Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Overt Hepatic Encephalopathy (OHE) Report Key Strengths

  • 10-Years Forecast
  • 7MM Coverage
  • OHE Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Overt Hepatic Encephalopathy (OHE) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the OHE’s market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the OHE’s total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest OHE market size during the forecast period (2021–2030)?
  • At what CAGR, the OHE market is expected to grow at the 7MM level during the forecast period (2021–2030)?
  • What would be the OHE market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the OHE market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of OHE?
  • What is the historical OHE patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient population of OHE at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to OHE?
  • Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of OHE during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of OHE along with the approved therapy?
  • What are the current treatment guidelines for the treatment of OHE in the US and Europe?
  • What are the OHE marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of OHE?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of OHE?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the OHE therapies?
  • What are the recent therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for OHE and their status?
  • What are the key designations that have been granted for the emerging therapies for OHE?
  • What are the 7MM historical and forecasted market of OHE?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the OHE.
  • To understand the future market competition in the OHE market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for OHE in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the OHE market.
  • To understand the future market competition in the OHE market.

1. Key Insights

2. Report Introduction

3. Overt Hepatic Encephalopathy (OHE) Market Overview at a Glance

3.1. Market Share (%) Distribution of OHE by Therapies in 2018

3.2. Market Share (%) Distribution of OHE by Therapies in 2030

4. Overt Hepatic Encephalopathy Market: Future Perspective

5. Executive Summary of Overt Hepatic Encephalopathy (OHE)

6. Disease Background and Overview

6.1. Introduction

6.2. Classification of Hepatic Encephalopathy (HE)

6.3. Symptoms

6.4. Cause and Risk Factors

6.5. Pathophysiology

6.6. Pathogenesis

6.7. Diagnosis

6.7.1. Differential Diagnosis for HE

6.7.2. Diagnostic Algorithm

6.7.3. Diagnostic Guidelines

6.7.3.1. Hepatic Encephalopathy in Chronic Liver Disease 2014 Practice Guideline by AASLD and EASL

6.7.3.2. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)

7. Treatment and Management

7.1. Line of therapies for the treatment of Hepatic Encephalopathy (HE)

7.2. Treatment Algorithm

7.3. Treatment Guidelines

7.3.1. Practice Guideline on Hepatic Encephalopathy from the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver

7.3.2. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology of Epidemiology

8.3. Assumptions and Rationale: 7MM

8.4. Total Diagnosed Prevalent Cases of Cirrhosis (Hospitalization Cases of Cirrhosis) in the 7MM

8.5. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy (HE) in the 7MM

8.6. Total Diagnosed Prevalent Cases of Overt Hepatic Encephalopathy (OHE) in the 7MM

8.7. The United States

8.7.1. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States

8.7.2. Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States

8.7.3. Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States

8.7.4. Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States

8.8. EU-5

8.8.1. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5

8.8.2. Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5

8.8.3. Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5

8.8.4. Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5

8.9. Japan

8.9.1. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in Japan

8.9.2. Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan

8.9.3. Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan

8.9.4. Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan

9. Patient Journey

10. Marketed Therapies

10.1. Xifaxan: Salix Pharmaceuticals/Bausch Health

10.1.1. Product Description

10.1.2. Regulatory Milestones

10.1.3. Research and Development

10.1.4. Clinical Trials Information

10.1.5. Safety and Efficacy

10.1.6. Product Profile

11. Emerging Drugs

11.1. Key Cross Competition

11.2. AXA1665: Axcella Health, Inc.

11.2.1. Product Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.2.7. Analysts’ Views

11.3. GR3027 (Golexanolone): Umecrine Cognition

11.3.1. Product Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.3.6. Analysts’ Views

11.4. OCR-002 (MNK-6105/MNK-6106): Mallinckrodt Therapeutics

11.4.1. Product Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Safety and Efficacy

11.4.6. Product Profile

11.4.7. Analysts’ Views

11.5. VE303: Vedanta Biosciences/Patricia Bloom

11.5.1. Product Description

11.5.2. Clinical Development

11.5.3. Clinical Trials Information

11.5.4. Product Profile

12. Overt Hepatic Encephalopathy (OHE): Seven Major Market Analysis

12.1. Key Findings

12.2. Methodology of Overt Hepatic Encephalopathy (OHE) Market

12.3. Market Size of Overt Hepatic Encephalopathy in the 7MM

12.4. Market Size of Overt Hepatic Encephalopathy by Therapies in the 7MM

12.5. Emerging Drug Analysis

12.6. Key Market Forecast Assumptions

12.7. Attribute Analysis

12.8. Market Outlook

12.9. Market size of Overt Hepatic Encephalopathy in the United States

12.9.1. Total Market size of Overt Hepatic Encephalopathy

12.9.2. Market Size by Therapies

12.10. Market size of Overt Hepatic Encephalopathy in EU-5

12.10.1. Total Market size of Overt Hepatic Encephalopathy in EU5

12.10.2. Market Size by Therapies

12.11. Market size of Overt Hepatic Encephalopathy in Japan

12.11.1. Total Market size of Overt Hepatic Encephalopathy

12.11.2. Market Size by Therapies

13. KOL Views

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. Reimbursement and Market Access

18.1. United States

18.2. Europe

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Table

Table 1: Summary of OHE Market and Epidemiology (2018–2030)

Table 2: Key Events

Table 3: Clinical Description of Hepatic Encephalopathy (Adapted from AASLD-EASL Guideline, 2014)

Table 4: West Haven Criteria for HE and symptoms

Table 5: The Five Clinical Patterns of HE Presentation

Table 6: Stages of HE

Table 7: Differential Diagnosis: Alternative Causes of Encephalopathy Depending on Clinical Patterns

Table 8: Common Treatment Options for Hepatic Encephalopathy

Table 9: Precipitating Factors of OHE

Table 10: Concomitant medical conditions that can affect patients with overt hepatic encephalopathy

Table 11: Treatment Summary

Table 12: Practice Guideline on Hepatic Encephalopathy from the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver

Table 13: Total Diagnosed Prevalent Cases of Cirrhosis (Hospitalization Cases of Cirrhosis) in the 7MM, in Thousand (2018–2030)

Table 14: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy (HE) in the 7MM (2018–2030)

Table 15: Total Diagnosed Prevalent Cases of Overt Hepatic Encephalopathy (OHE) in the 7MM (2018–2030)

Table 16: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2018–2030)

Table 17: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2018–2030)

Table 18: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States (2018–2030)

Table 19: Type-Specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2018–2030)

Table 20: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in EU-5 (2018–2030)

Table 21: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5 (2018–2030)

Table 22: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU5 (2018–2030)

Table 23: Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU5 (2018–2030)

Table 24: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in Japan (2018–2030)

Table 25: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2018–2030)

Table 26: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2018–2030)

Table 27: Type-Specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2018–2030)

Table 28: Rifaximin, Clinical Trial Description, 2021

Table 29: Comparison of emerging drugs under development

Table 30: AXA1665, Clinical Trial Description, 2021

Table 31: OCR-002 (MNK-6105/ MNK-6106), Clinical Trial Description, 2021

Table 32: VE303, Clinical Trial Description, 2021

Table 33: Market Size of Overt Hepatic Encephalopathy in the 7MM in USD Million (2018–2030)

Table 34: Market Size of Overt Hepatic Encephalopathy by therapies in the 7MM in USD Million (2018–2030)

Table 35: Key Market Forecast Assumptions for MNK-6105 (IV)

Table 36: Key Market Forecast Assumptions for Rifaximin (SSD)

Table 37: United States Market Size of Overt Hepatic Encephalopathy in USD Million (2018–2030)

Table 38: Market Size of Overt Hepatic Encephalopathy by therapies in the US, in USD Million (2018–2030)

Table 39: EU-5 Market Size of Overt Hepatic Encephalopathy in USD Million (2018–2030)

Table 40: Market Size of Overt Hepatic Encephalopathy by therapies in EU5, in USD Million (2018–2030)

Table 41: Market Size of Overt Hepatic Encephalopathy in Japan, in USD Million (2018–2030)

Table 42: Market Size of Overt Hepatic Encephalopathy by therapies in Japan, in USD Million (2018–2030)

List of Figures

Figure 1: Symptoms of HE

Figure 2: Grading of the symptoms of HE

Figure 3: Risk Factors of HE

Figure 4: Pathophysiology of HE

Figure 5: Ammonia Trafficking in HE from an Organism (left panel) and an Organ (right panel) Perspective

Figure 6: Diagnostic tree for HE, ammonia reducing treatments

Figure 7: The Classification of HE

Figure 8: Management of patients with hepatic encephalopathy (HE)

Figure 9: Treatment algorithm for patients with Overt Hepatic Encephalopathy (OHE)

Figure 10: Total Diagnosed Prevalent Cases of Cirrhosis (Hospitalization Cases of Cirrhosis) in the 7MM (2018–2030)

Figure 11: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy (HE) in the 7MM (2018–2030)

Figure 12: Total Diagnosed Prevalent Cases of Overt Hepatic Encephalopathy (OHE) in the 7MM (2018–2030)

Figure 13: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2018–2030)

Figure 14: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2018–2030)

Figure 15: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2018–2030)

Figure 16: Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2018–2030)

Figure 17: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in EU-5 (2018–2030)

Figure 18: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5 (2018–2030)

Figure 19: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5 (2018-2030)

Figure 20: Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5 (2018-2030)

Figure 21: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in Japan (2018–2030)

Figure 22: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2018–2030)

Figure 23: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2018–2030)

Figure 24: Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2018–2030)

Figure 25: Patient Journey

Figure 26: Market Size of Overt Hepatic Encephalopathy in the 7MM in USD Million (2018–2030)

Figure 27: Market Size of Overt Hepatic Encephalopathy by therapies in the 7MM in USD Million (2018–2030)

Figure 28: Market Size of Overt Hepatic Encephalopathy in the United States, USD Millions (2018–2030)

Figure 29: Market size of Overt Hepatic Encephalopathy by therapies in the United States, in USD Million (2018–2030)

Figure 30: Market Size of Overt Hepatic Encephalopathy in EU5, USD Millions (2018–2030)

Figure 31: Market Size of Overt Hepatic Encephalopathy by therapies, in EU5, in USD Million (2018–2030)

Figure 32: Market Size of Overt Hepatic Encephalopathy in Japan, USD Millions (2018–2030)

Figure 33: Market Size of Overt Hepatic Encephalopathy by therapies in Japan, in USD Million (2018–2030)

Figure 34: Market Drivers

Figure 35: Market Barriers

Figure 36: SWOT Analysis

Figure 37: Unmet Needs

Salix Pharmaceuticals
Bausch Health
Axcella Health, Inc.
Umecrine Cognition
Mallinckrodt Therapeutics
Vedanta Biosciences
Patricia Bloom

 

Forward to Friend

Need A Quote